

VPA22664/021/001

Norodine 24 % Solution for Injection

Variation	Summary	Date
Vet - B40	VNRA - Vet - B40 - Replacement or addition of a supplier of packaging components or devices - B40 Changes to the quality part of the dossier: Replacement or addition of a supplier of packaging components or devices (when mentioned in the dossier)	03/10/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	28/06/24
Vet - F.II.d.1 z)	VRA-R - Vet - F.II.d.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.1 z) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	14/11/23
Vet - F.II.d.1 z)	VRA-R - Vet - F.II.d.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.1 z) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	14/11/23
Vet - F.II.d.1 a)	VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	14/11/23
Vet - F.II.d.1 a)	VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	14/11/23

Vet - F.II.d.2 b)	VRA-R - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	14/11/23
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	14/11/23
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	14/11/23
Vet - B30 a)	VNRA - Vet - B30 a) - a) Tightening of specification limits - B30 a) Changes to the quality part of the dossier: Change in the specification parameters or limits of the finished product: — tightening of specification limits	13/11/23
Vet - B27 b)	VNRA - Vet - B27 b) - b) Addition of a new in-process test and limits - B27 b) Changes to the quality part of the dossier: Change to in-process tests or limits applied during the manufacture of the finished product: — addition of a new in-process test and limits	13/11/23
Vet - C2	VNRA - Vet - C2 - Change(s) in the Summary of Product Characteristics (SPC), labelling or package leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6 - C2 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the Summary of Product Characteristics (SPC), labelling or package leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6	25/07/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	20/07/23
Vet - F.III.1 a) 1.	VRA-R - Vet - F.III.1 a) 1. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. 1. New certificate for a non-sterile active substance that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed to be endotoxin free - F.III.1 a) 1. Quality Changes - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur.	20/06/23

	certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate for a non-sterile active substance that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed to be endotoxin free	
Vet - B3 t)	VNRA - Vet - B3 t) - t) Deletion of a Ph. Eur. CEP - B3 t) Changes to the quality part of the dossier: Deletion of a Ph. Eur. CEP — for an active substance; — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	31/03/23
Vet - B3 t)	VNRA - Vet - B3 t) - t) Deletion of a Ph. Eur. CEP - B3 t) Changes to the quality part of the dossier: Deletion of a Ph. Eur. CEP — for an active substance; — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	30/03/23